The reported discussions come at a time when Allergan is attempting to shake off a $53 billion acquisition bid from Quebec, Canada-based Valeant Pharmaceuticals, according to the report. Allergan believes the bid from Valeant is “underpriced and too risky,” according to the report.
If Allergan and Salix were to merge, the newly joined market value could make it more difficult for Valeant to successfully acquire Allergan due to the increased value and complexity, according to the report.
More articles on acquisitions:
Hospital M&A activity dips slightly in first half of 2014
Prime Healthcare, Daughters of Charity Health reportedly considering merger
MedAssets to acquire Sg2
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.